Print ISSN:-2581-8112

Online ISSN:-2581-9151

CODEN : IIJOAT




Downlaod Files

   


Article Access statistics

Viewed: 1573

PDF Downloaded: 607


Efficacy of celecoxib and diclofenac in the pain management of Rheumatoid Arthritis: A Clinical study


Full Text PDF


Original Article

Author Details : Kolla Saketh, Y. Thimma Reddy, J. Satyanarayana, Gattu Naresh

Volume : 2, Issue : 1, Year : 2016

Article Page : 13-14


Suggest article by email

Get Permission

Abstract

Background: Rheumatoid arthritis(RA) is a systemic auto-immune disorder, involving inflammation of the joints. Non-Steroidal Anti-inflammatory drugs (NSAIDs) are used to reduce the symptoms RA but the Non- Selective NSAIDs such as diclofenac is associated with significant gastro-intestinal side effects including bleeding, ulceration and perforations. NSAIDs like celecoxib which is selective cyclooxygenase (COX) II inhibitor is used widely in order to reduce the GI toxicity.
Objectives: To compare the efficacy of celecoxib and diclofenac in the pain management of RA.
Methods: 30 RA patients were included in the study. Group A (15 patients) was given celecoxib 100mg twice daily (200mg/day) and Group B(15 patients) was given diclofenac 50mg thrice daily(150mg/day) for 6 weeks. Pain was assessed before the start of medication and at the end of 6 weeks using Visual analogue score (VAS). 
Results: Mean age, mean pre-medication VAS scores in both groups was similar. VAS scores were decreased in both groups at the end of 6 weeks, however VAS scale was more less in Group A when compared with Group B.
Interpretation and conclusions: Celecoxib is more effective when compared with diclofenac in pain management of Rheumatoid arthritis.

Key Words: Rheumatoid Arthritis, Selective COX II inhibitors, NSAIDs, Pain

 



How to cite : Saketh K, Reddy Y T, Satyanarayana J, Naresh G, Efficacy of celecoxib and diclofenac in the pain management of Rheumatoid Arthritis: A Clinical study. IP Int J Orthop Rheumatol 2016;2(1):13-14


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution 4.0 International License, which allows others to remix, and build upon the work, the licensor cannot revoke these freedoms as long as you follow the license terms.